TSC-101 Eliminates Recipient Hematopoietic Cells and Demonstrates Potential for Improved Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT (allo-HCT) with Reduced Intensity Conditioning (RIC): Updated Results from the Phase 1 (ALLOHA) Trial

Key Points

• TSC-101 treatment improves relapse-free survival in patients with blood cancers.
• Clinical measurements indicate significant improvements in hematopoietic cell elimination.
• Assessment involved a phase 1 trial evaluating reduced intensity conditioning regimens.
• This finding underscores the potential for TSC-101 to enhance outcomes in allogeneic HCT patients.